PW01-002 – Colchicine resistant FMF in Turkish children
نویسندگان
چکیده
Results Eleven patients with mean age of 12,7±7,7 years (median 14, ranging 1,5-23 years) were studied. These patients were on colchicine treatment for a mean of 5,5±4,2 years. In one patient initially etanercept was used however, this was switched to anakinra since there was no repsonse to anti TNF treatment. A total of 7 patiets were started anakinra, however, 2 had local reactions and 2 was unresponsive; they were switched to canakinumab treatment and they all responded with normal acute phase reactants. At this time a total of 8 patients are now being treated with canakinumab with a mean duration of 10,8 ±6,8 months and 3 patients with anakinra with a mean duration of 19,6 months. One patient who is on anakinra treatment has HIDS mutation as well. There were no side effects.
منابع مشابه
PW01-015 – Canakinumab in adults with colchicin resistant FMF
Introduction Familial Mediterranean fever (FMF) is associated with variations in the MEFV gene resulting in proteolytic activation of IL-1b through the inflammasome complex. There is no established treatment available for those resistant or intolerant to standard of care colchicine treatment. Canakinumab, a fully human selective anti-IL-1b monoclonal antibody with a half-life of ~4-weeks binds ...
متن کاملPW01-031 – Treatment of FMF in middle and old age
Introduction Current recommendations for the treatment of familial Mediterranean fever (FMF) are based largely on the observation of FMF patients receiving colchicine therapy in childhood and young age. The adequate colchicine therapy led to more and more patients survive to that age. In addition, there are national peculiarities of FMF. For example, in Armenia, even before the massive use of c...
متن کاملPW01-007 – Colchicine brand switching in FMF patients
Introduction In July of 2009 the U.S. Food and Drug Administration enacted new regulation of colchicine under the “Unapproved Drugs Program.” Like other old drugs that were on the market before the existence of the FDA, colchicine had never been subjected to FDA-required safety and efficacy trials. One company elected to put colchicine through the FDA’s approval protocol and when approval was g...
متن کاملPW01-010 – The effect of pregnancy on disease course in FMF
Methods All pregnant FMF patients treated at the FMF clinic of the Sheba Medical Center from May 2010 onwards, consenting to participate in this observational study, were studied prospectively for the occurrence of attacks. Attacks were recorded by patients in diaries provided on enrollment and relied by phone to a study coordinator on a monthly telephone call or on a pre-specified physician vi...
متن کاملDapsone as an Alternative Therapy in Children with Familial Mediterranean Fever
OBJECTIVE Familial Mediterranan Fever is an hereditary autoinflammatory disease that presents with recurrent febrile attacks and poly serositis. Colchicine is the only known treatment in this diease. However, nearly 5-10% of patients are resistant to colchicines. There are many different modalities in colchicine resistant patients, biologic and immunosupressive drugs being the known ones. We st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 11 شماره
صفحات -
تاریخ انتشار 2013